An expert description of the endocannabinoid system (ECS) was entrusted to Dr. Hana Krninská Liškařová. We also asked her about the future of terpenes and provided her with materials from the PubMed database and other expert sources. It turned out, however, that she already knew it well. Dr. Krninská tested our drops and in this article you'll learn how her team reacted to them too.
What Is the Endocannabinoid System (ECS)?
The endocannabinoid system is an absolutely fantastic matter. I'm a little sorry my colleagues don't know much about it. I didn't know much about it either until they allowed us to prescribe medicinal cannabis. At that moment I began studying and discovered what an incredible and fantastic thing it is.
We can imagine the ECS as a symphony orchestra, where the conductor is a key figure. The orchestra represents various parts of our body. Each instrument has its unique sound and role, but for them to play beautifully together and create harmony, a skillful conductor is needed. This conductor is precisely our endocannabinoid system.
Beta-Caryophyllene (BCP) and Its Role
One of the significant terpenes that could significantly shake things up is Beta-caryophyllene. The ability of BCP to selectively activate cannabinoid receptor type 2 was scientifically first described in 2008 by a team led by Jürgen Gertsch in PNAS.
Who Can Benefit from BCP?
Chronic pain, autoimmune diseases, lung inflammations, skin problems, psychological difficulties, and neurodegenerative diseases. A significant role of BCP is in pain modulation—no tolerance develops unlike with opiates. It works synergistically with paracetamol and NSAIDs.
— Dr. Hana Krninská Liškařová